Single Subject Neratinib in Bladder Cancer (NRR)

NO_LONGER_AVAILABLE

Conditions studied: Bladder Cancer

In brief

This study will be a single subject study to evaluate the efficacy of the HER2 kinase inhibitor, neratinib, in a patient with metastatic bladder cancer harboring a HER2-GRB7 gene fusion.

Key facts

Study ID

NCT01956253

Run by

UNC Lineberger Comprehensive Cancer Center

Starts

2013-07-01

Expected to finish

2014-06-01

Last updated by the study team

2017-03-14

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• none

You may not qualify if…

• none
• We have received FDA approval for a single subject Investigational New Drug (IND) Application to treat a specific patient with the HER2 kinase inhibitor neratinib. Therefore there is no inclusion / exclusion criteria.

Where it is running

• North Carolina Cancer Hospital (UNC) — Chapel Hill, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.